Premium
Platelet sensitivity to antiaggregatory prostaglandins (PGE 1 , D 2 , I 2 ) in patients with peripheral vascular disease
Author(s) -
Fitscha P.,
Kaliman J.,
Sinzinger H.
Publication year - 1985
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830190103
Subject(s) - platelet , medicine , prostaglandin e , endocrinology , diabetes mellitus , peripheral , receptor , prostaglandin , prostaglandin e1 , risk factor
Platelet sensitivity to antiaggregatory prostaglandins (PGI 2 , PGE 1 , PGD 2 ) was studied in 143 patients (122 male) with angiographically proven peripheral vascular disease and compared with age‐matched clinically normal controls. Patients had a significantly lower platelet sensitivity to PGI 2 , PGE 1 , and PGD 2 , than controls. Clinical stages had no significant influence on the platelet sensitivity to PGI 2 and PGE 1 . Patients with stage IIa had a lower sensitivity to PGD 2 than patients with stage IV, the difference not being significant. Analyzing the influence of risk factors like diabetes, hyperlipoproteinemia, or smoking, there seemed to be an inverse relation between risk factors and platelet sensitivity to PGI 2 and PGE 1 . Smokers especially, together with smokers exhibiting an additional risk factor, exhibited the highest prostaglandin consumption (PGI 2 , PGE 1 ) and therefore the lowest platelet sensitivity. However, it has to be emphasized that the differences were not significant. There was a significant correlation between platelet sensitivity to PGI 2 and PGE 1 , whereas this was not the case between the respective sensitivities to PGI 2 , and PGD 2 . This supports the hypothesis that both these prostaglandins (PGI 2 , PGE 1 ) share the same receptor on the platelet surface, whercas PGD 2 has its own receptor.